Antimicrobial activity of everninomicin against clinical isolates of Enterococcus spp., Staphylococcus spp., and Streptococcus spp. tested by Etest
- 1 January 2001
- journal article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 7 (4) , 263-266
- https://doi.org/10.1007/s101560170025
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- In Vivo Activity of Evernimicin (SCH 27899) against Methicillin-Resistant Staphylococcus aureus in Experimental Infective EndocarditisAntimicrobial Agents and Chemotherapy, 2001
- Presence of Variations in Ribosomal Protein L16 Corresponding to Susceptibility of Enterococci to Oligosaccharides (Avilamycin and Evernimicin)Antimicrobial Agents and Chemotherapy, 2000
- In Vivo Activities of Evernimicin (SCH 27899) against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci in Experimental EndocarditisAntimicrobial Agents and Chemotherapy, 2000
- In Vivo Activity and Pharmacokinetics of Ziracin (SCH27899), a New Long-Acting Everninomicin Antibiotic, in a Murine Model of Penicillin-Susceptible or Penicillin-Resistant Pneumococcal PneumoniaAntimicrobial Agents and Chemotherapy, 2000
- Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of ActionAntimicrobial Agents and Chemotherapy, 2000
- Antimicrobial activity and spectrum of SCH27899 (ziracin®) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality controlDiagnostic Microbiology and Infectious Disease, 1999
- Antimicrobial activity of SCH27899 (Ziracin®), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/Etest method evaluations and quality control guidelinesDiagnostic Microbiology and Infectious Disease, 1999